Cefamandole/Cefatrizine 221

Total Page:16

File Type:pdf, Size:1020Kb

Cefamandole/Cefatrizine 221 Cefamandole/Cefatrizine 221 Cefamandole Sodium (BANM, rINNM) hours and high urinary concentrations are achieved. Pharmacopoeias. In Eur. (see p.vii), Jpn, and US. Cefamandol sódico; Céfamandole Sodique; Cephamandole So- Probenecid competes for renal tubular secretion with US also includes Cephapirin Benzathine for veterinary use. Ph. Eur. 6.2 (Cefapirin Sodium). A white or pale yellow powder. dium; Natrii Cefamandolum. cefamandole resulting in higher and prolonged plasma Soluble in water; practically insoluble in dichloromethane. A 1% Натрий Цефамандол concentrations of cefamandole. Therapeutic concen- solution in water has a pH of 6.5 to 8.5. Protect from light. C18H17N6NaO5S2 = 484.5. trations of cefamandole are achieved in bile. USP 31 (Cephapirin Sodium). A white to off-white crystalline CAS — 30034-03-8. Cefamandole is removed by haemodialysis to some powder, odourless or having a slight odour. Very soluble in wa- ATC — J01DC03. extent. ter; insoluble in most organic solvents. pH of a solution in water ATC Vet — QJ01DC03. containing the equivalent of cefapirin 1% is between 6.5 and 8.5. Store in airtight containers. Adverse Effects and Precautions Uses and Administration Cefamandole is a second-generation cephalosporin an- Profile As for Cefalotin Sodium, p.219. Cefapirin is a first-generation cephalosporin antibacterial with As mentioned under Cefalotin, cephalosporins with an tibacterial used in the treatment of infections due to actions and uses very similar to those of cefalotin (p.219). It is N-methylthiotetrazole side-chain such as cefamandole susceptible bacteria and for surgical infection prophy- used as the sodium salt but doses are expressed in terms of cefa- (and possibly those with methylthiadiazolethiol or N- laxis. pirin base; 1.05 g of cefapirin sodium is equivalent to about 1 g It is given principally as cefamandole nafate (the sodi- of cefapirin. The usual dose is the equivalent of 0.5 to 1 g of ce- methylthiotriazine side-chains as well) may produce fapirin every 4 to 6 hours by intramuscular injection or intrave- bleeding disorders associated with hypoprothrombin- um salt of cefamandole formyl ester). Doses are ex- nously. In severe infections up to 12 g daily may be given, pref- aemia and/or platelet disorders. pressed in terms of the equivalent amount of cefaman- erably intravenously. Sodium content. 1.05 g of cefamandole sodium and 1.11g of dole; 1.05 g of cefamandole sodium and 1.11 g of Administration in renal impairment. Reduced doses of ce- cefamandole nafate each contain about 2.2 mmol of sodium. cefamandole nafate are each equivalent to about 1 g of fapirin sodium may be necessary in patients with renal impair- cefamandole. It is given by deep intramuscular injec- ment. One regimen, based on creatinine clearance (CC), that has Interactions tion, by slow intravenous injection over 3 to 5 minutes, been suggested is: A disulfiram-like interaction with alcohol may occur or by intermittent or continuous infusion in doses of 0.5 • CC 5 to 20 mL/minute: 1 g every 12 hours and has been attributed to the N-methylthiotetrazole to 2 g every 4 to 8 hours for adults depending on the • CC less than 5 mL/minute: 1 g every 24 hours side-chain of cefamandole; patients should avoid alco- severity of the infection. Children over 1 month of age Patients undergoing haemodialysis may receive 7.5 to 15 mg/kg hol during, and for at least several days after, cefaman- may be given 50 to 100 mg/kg daily in equally divided after each dialysis. dole treatment. Interactions are also possible with prep- doses; 150 mg/kg daily may be given in severe infec- Sodium content. Each g of cefapirin sodium contains about arations containing significant amounts of alcohol. tions, but this dose should not be exceeded. For details 2.2 mmol of sodium. Cefamandole, and other cephalosporins with an N- of reduced doses in patients with renal impairment, see Preparations methylthiotetrazole side-chain, may enhance the hypo- below. If cefamandole is used with an aminoglycoside, USP 31: Cephapirin for Injection. the drugs should be given separately. prothrombinaemic response to anticoagulants as dis- Proprietary Preparations (details are given in Part 3) cussed under Warfarin (p.1428). For surgical infection prophylaxis, a dose of 1 or 2 g Cz.: Cefatrexyl†; Fr.: Cefaloject; Gr.: Cefatrex†; Spain: Brisfirina. Probenecid reduces the renal clearance of cefamandole intravenously or intramuscularly 30 to 60 minutes be- and many other cephalosporins. fore surgical incision, followed by 1 or 2 g every 6 hours for 24 to 48 hours, is recommended. For patients Cefatrizine (BAN, USAN, pINN) ◊ References. undergoing procedures involving implantation of pros- 1. Portier H, et al. Interaction between cephalosporins and alcohol. BL-S640; Cefatrizina; Céfatrizine; Cefatrizinum; SKF-60771; S- Lancet 1980; ii: 263. thetic devices, cefamandole should be continued for up 640P. (7R)-7-(α-D-4-Hydroxyphenylglycylamino)-3-(1H-1,2,3-tri- 2. Drummer S, et al. Antabuse-like effect of β-lactam antibiotics. N to 72 hours. Children over 3 months of age may be Engl J Med 1980; 303: 1417–18. azol-4-ylthiomethyl)-3-cephem-4-carboxylic acid. treated similarly to adults and given 50 to 100 mg/kg Цефатризин daily in equally divided doses. Antimicrobial Action C18H18N6O5S2 = 462.5. Cefamandole is bactericidal and acts similarly to cefal- Administration in renal impairment. Doses of cefaman- CAS — 51627-14-6. otin, but has a broader spectrum of activity. It generally dole should be reduced for patients with renal impairment. After ATC — J01DB07. has similar or less activity against Gram-positive sta- an initial dose of 1 to 2 g the following maintenance doses have ATC Vet — QJ01DB07. been recommended based on creatinine clearance (CC): phylococci and streptococci, but is resistant to some • CC 50 to 80 mL/minute: 0.75 to 2 g every 6 hours beta-lactamases produced by Gram-negative bacteria. • CC 25 to 50 mL/minute: 0.75 to 2 g every 8 hours HO O It is more active than cefalotin against many of the En- • CC 10 to 25 mL/minute: 0.5 to 1.25 g every 8 hours HH terobacteriaceae including some strains of Entero- S • CC 2 to 10 mL/minute: 0.5 to 1 g every 12 hours N bacter, Escherichia coli, Klebsiella, Salmonella, and • CC less than 2 mL/minute: 0.25 to 0.75 g every 12 hours H some Proteus spp. However, resistance to cefamandole NH2 N SN Preparations O N and other beta lactams has emerged in some species, COOH NH notably Enterobacter, during treatment with cefaman- USP 31: Cefamandole Nafate for Injection. Proprietary Preparations (details are given in Part 3) dole. Cefamandole is very active in vitro against Hae- Austral.: Mandol; Austria: Mandokef; Belg.: Mandol; Cz.: Mandol†; Gr.: mophilus influenzae although an inoculum effect has Acemycin; Cefadin; Mandokef; Hong Kong: Mandol†; Hung.: Cefam; Cefatrizine Propylene Glycol (BANM, pINNM) Mandokef†; Indon.: Dardokef; Dofacef; Irl.: Kefadol†; Ital.: Cefam; Cema- been reported for beta-lactamase-producing strains. do; Lampomandol; Mancef; Mandokef†; Mandolsan†; Septomandolo†; Cefatrizina propilenglicol; Cefatrizinas propilenglikolis; Céfatrizine Like cefalotin, most strains of Bacteroides fragilis are Neth.: Mandol; NZ: Mandol; Pol.: Tarcefandol; Port.: Mandokef†; Rus.: propylèneglycol; Cefatrizin-propilénglikol; Cefatrizinpropyleng- Cefat (Цефат); Mandol (Мандол); S.Afr.: Kefdole†; Mandokef; Switz.: lykol; Cefatrizin-propylenglykol; Cefatrizinum propylen glycolum; resistant to cefamandole, as are Pseudomonas spp. Mandokef; Thai.: Cefadol; Cefmandol; Mandol†. Cefatrizinum Propylenglycolum; Kefatritsiinipropyleeniglykoli. ◊ References. (7R)-7-(α-D-4-Hydroxyphenylglycylamino)-3-(1H-1,2,3-triazol- 1. Sabath LD. Reappraisal of the antistaphylococcal activities of 4-ylthiomethyl)-3-cephem-4-carboxylate propylene glycol. first-generation (narrow-spectrum) and second-generation (ex- Cefapirin Sodium (BANM, pINNM) panded-spectrum) cephalosporins. Antimicrob Agents Chemoth- Цефатризин Пропиленгликол er 1989; 33: 407–11. BL-P-1322; Cefapirin sodná sůl; Cefapirina sódica; Céfapirine sodique; Cefapirinnatrium; Cefapirin-nátrium; Cefapirino natrio C18H18N6O5S2, (C3H8O2)n. CAS — 64217-62-5. Pharmacokinetics druska; Cefapirinum natricum; Cephapirin Sodium (USAN); Kefa- piriininatrium; Natrii Cefapirinum. Sodium (7R)-7-[2-(4-pyri- ATC — J01DB07. Cefamandole is poorly absorbed from the gastrointes- ATC Vet — QJ01DB07. tinal tract. It is given intramuscularly or intravenously, dylthio)acetamido]cephalosporanate; Sodium (7R)-3-ace- usually as the nafate which is rapidly hydrolysed to re- toxymethyl-7-[2-(4-pyridylthio)acetamido]-3-cephem-4-carbox- Pharmacopoeias. In Eur. (see p.vii) and Jpn. ylate. Ph. Eur. 6.2 (Cefatrizine Propylene Glycol). A white or almost lease cefamandole in vivo. Peak plasma concentrations Натрий Цефапирин white powder. Slightly soluble in water; practically insoluble in for cefamandole of about 13 and 25 micrograms/mL alcohol and in dichloromethane. C17H16N3NaO6S2 = 445.4. have been achieved 0.5 to 2 hours after intramuscular CAS — 21593-23-7 (cefapirin); 24356-60-3 (cefapirin so- Profile doses of 0.5 and 1 g respectively; concentrations are dium). Cefatrizine is a cephalosporin antibacterial with actions and uses very low after 6 hours. About 70% is bound to plasma ATC — J01DB08. similar to those of cefalexin (p.218), although it might be more proteins. The plasma half-life varies from about 0.5 to ATC Vet — QJ01DB08. active in vitro. It is given orally as the base or, more often, as a 1.2 hours depending on the route of injection;
Recommended publications
  • Download Download
    VOLUME 7 NOMOR 2 DESEMBER 2020 ISSN 2548 – 611X JURNAL BIOTEKNOLOGI & BIOSAINS INDONESIA Homepage Jurnal: http://ejurnal.bppt.go.id/index.php/JBBI IN SILICO STUDY OF CEPHALOSPORIN DERIVATIVES TO INHIBIT THE ACTIONS OF Pseudomonas aeruginosa Studi In Silico Senyawa Turunan Sefalosporin dalam Menghambat Aktivitas Bakteri Pseudomonas aeruginosa Saly Amaliacahya Aprilian*, Firdayani, Susi Kusumaningrum Pusat Teknologi Farmasi dan Medika, BPPT, Gedung LAPTIAB 610-612 Kawasan Puspiptek, Setu, Tangerang Selatan, Banten 15314 *Email: [email protected] ABSTRAK Infeksi yang diakibatkan oleh bakteri gram-negatif, seperti Pseudomonas aeruginosa telah menyebar luas di seluruh dunia. Hal ini menjadi ancaman terhadap kesehatan masyarakat karena merupakan bakteri yang multi-drug resistance dan sulit diobati. Oleh karena itu, pentingnya pengembangan agen antimikroba untuk mengobati infeksi semakin meningkat dan salah satu yang saat ini banyak dikembangkan adalah senyawa turunan sefalosporin. Penelitian ini melakukan studi mengenai interaksi tiga dimensi (3D) antara antibiotik dari senyawa turunan Sefalosporin dengan penicillin-binding proteins (PBPs) pada P. aeruginosa. Tujuan dari penelitian ini adalah untuk mengklarifikasi bahwa agen antimikroba yang berasal dari senyawa turunan sefalosporin efektif untuk menghambat aktivitas bakteri P. aeruginosa. Struktur PBPs didapatkan dari Protein Data Bank (PDB ID: 5DF9). Sketsa struktur turunan sefalosporin digambar menggunakan Marvins Sketch. Kemudian, studi mengenai interaksi antara antibiotik dan PBPs dilakukan menggunakan program Mollegro Virtual Docker 6.0. Hasil yang didapatkan yaitu nilai rerank score terendah dari kelima generasi sefalosporin, di antaranya sefalotin (-116.306), sefotetan (-133.605), sefoperazon (-160.805), sefpirom (- 144.045), dan seftarolin fosamil (-146.398). Keywords: antibiotik, penicillin-binding proteins, P. aeruginosa, sefalosporin, studi interaksi ABSTRACT Infections caused by gram-negative bacteria, such as Pseudomonas aeruginosa, have been spreading worldwide.
    [Show full text]
  • AMEG Categorisation of Antibiotics
    12 December 2019 EMA/CVMP/CHMP/682198/2017 Committee for Medicinal Products for Veterinary use (CVMP) Committee for Medicinal Products for Human Use (CHMP) Categorisation of antibiotics in the European Union Answer to the request from the European Commission for updating the scientific advice on the impact on public health and animal health of the use of antibiotics in animals Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 29 October 2018 Adopted by the CVMP for release for consultation 24 January 2019 Adopted by the CHMP for release for consultation 31 January 2019 Start of public consultation 5 February 2019 End of consultation (deadline for comments) 30 April 2019 Agreed by the Antimicrobial Advice ad hoc Expert Group (AMEG) 19 November 2019 Adopted by the CVMP 5 December 2019 Adopted by the CHMP 12 December 2019 Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Categorisation of antibiotics in the European Union Table of Contents 1. Summary assessment and recommendations .......................................... 3 2. Introduction ............................................................................................ 7 2.1. Background ........................................................................................................
    [Show full text]
  • Pharmacokinetic Evaluation of Amoxicillin/Clavulanicacid And
    PHARMACOKINETIC EVALUATION OF AMOXICILLIN/CLAVULANICACID AND ANTACID INTERACTION Anab Fatima B.Pharm, M.Phil.(Pharmaceutics) Thesis submitted for the award of degree of Ph.D In Pharmaceutics DEPARTMENT OF PHARMACEUTICS FACULTY OF PHARMACY UNIVERSITY OF KARACHI. 1 2 In the name of ALLAH The most Beneficient and tha most Merciful………………. ALLAHUMA SALLEY ALA SYEDENA MAULANA MUHAMMEDUN WA ALA AALEHYY WA ASHABHI BARIK WASALLIM WA SALLO ALEHEY SURAT AL-FATIHAH 1. IN THE NAME OF ALLAH,THE MOST GRACIOUS,THE MOST MERCIFUL. 3 2. ALL THE PRAISES AND THANKS BE TO ALLAH,THE LORD OF THE A LAMIN(MANKIND,JINN AND ALL THAT EXIST). 3. THE MOST GRACIOUS,THE MOST MERCIFUL. 4. THE ONLY OWNER(AND THE ONLY RULING JUDGE)OF THE DAY OF RECOMPENSE(THE DAY OF RESURRECTION). 5. YOU(ALONE) WE WORSHIP,AND YOU(ALONE) WE ASK FOR HELP(FOR EACH AND EVERY THING). 6. GUIDE US TO STRAIGHT WAY. 7. THE WAY OF THOSE WHOM YOU HAVE BESTOWED YOUR GRACE,NOT(THE WAY) OF THOSE WHO EARNED YOUR ANGER NOR OF THOSE WHO WENT ASTRAY.(AAMEEN) 4 DEDICATED TO: My beloved Parentral Grand Father(late),Grand Mother(late),Parents and all those persons whose prayers bring me to this stage. ACKNOWLEDGEMENT “If ALLAH assist you, then there is none that can overcome you” (Holy Quran 3:160) All praise to Almighty Allah who gives me strength, confidence and courage to complete the thesis. I am heartiest thankful to my research supervisor Prof.Dr.S.Baqir.S.Naqvi for his valuable guidance, sincere advice, moral support and encouragement throughout the research project.
    [Show full text]
  • Consideration of Antibacterial Medicines As Part Of
    Consideration of antibacterial medicines as part of the revisions to 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) Section 6.2 Antibacterials including Access, Watch and Reserve Lists of antibiotics This summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2019 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee on Selection and Use of Essential Medicines (see The selection and use of essential medicines: report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). Geneva: World Health Organization; 2019 (WHO Technical Report Series, No. 1021). Licence: CC BY-NC-SA 3.0 IGO: https://apps.who.int/iris/bitstream/handle/10665/330668/9789241210300-eng.pdf?ua=1) and Corrigenda (March 2020) – TRS1021 (https://www.who.int/medicines/publications/essentialmedicines/TRS1021_corrigenda_March2020. pdf?ua=1). Executive summary of the report: https://apps.who.int/iris/bitstream/handle/10665/325773/WHO- MVP-EMP-IAU-2019.05-eng.pdf?ua=1.
    [Show full text]
  • Computational Antibiotics Book
    Andrew V DeLong, Jared C Harris, Brittany S Larcart, Chandler B Massey, Chelsie D Northcutt, Somuayiro N Nwokike, Oscar A Otieno, Harsh M Patel, Mehulkumar P Patel, Pratik Pravin Patel, Eugene I Rowell, Brandon M Rush, Marc-Edwin G Saint-Louis, Amy M Vardeman, Felicia N Woods, Giso Abadi, Thomas J. Manning Computational Antibiotics Valdosta State University is located in South Georgia. Computational Antibiotics Index • Computational Details and Website Access (p. 8) • Acknowledgements (p. 9) • Dedications (p. 11) • Antibiotic Historical Introduction (p. 13) Introduction to Antibiotic groups • Penicillin’s (p. 21) • Carbapenems (p. 22) • Oxazolidines (p. 23) • Rifamycin (p. 24) • Lincosamides (p. 25) • Quinolones (p. 26) • Polypeptides antibiotics (p. 27) • Glycopeptide Antibiotics (p. 28) • Sulfonamides (p. 29) • Lipoglycopeptides (p. 30) • First Generation Cephalosporins (p. 31) • Cephalosporin Third Generation (p. 32) • Fourth-Generation Cephalosporins (p. 33) • Fifth Generation Cephalosporin’s (p. 34) • Tetracycline antibiotics (p. 35) Computational Antibiotics Antibiotics Covered (in alphabetical order) Amikacin (p. 36) Cefempidone (p. 98) Ceftizoxime (p. 159) Amoxicillin (p. 38) Cefepime (p. 100) Ceftobiprole (p. 161) Ampicillin (p. 40) Cefetamet (p. 102) Ceftoxide (p. 163) Arsphenamine (p. 42) Cefetrizole (p. 104) Ceftriaxone (p. 165) Azithromycin (p.44) Cefivitril (p. 106) Cefuracetime (p. 167) Aziocillin (p. 46) Cefixime (p. 108) Cefuroxime (p. 169) Aztreonam (p.48) Cefmatilen ( p. 110) Cefuzonam (p. 171) Bacampicillin (p. 50) Cefmetazole (p. 112) Cefalexin (p. 173) Bacitracin (p. 52) Cefodizime (p. 114) Chloramphenicol (p.175) Balofloxacin (p. 54) Cefonicid (p. 116) Cilastatin (p. 177) Carbenicillin (p. 56) Cefoperazone (p. 118) Ciprofloxacin (p. 179) Cefacetrile (p. 58) Cefoselis (p. 120) Clarithromycin (p. 181) Cefaclor (p.
    [Show full text]
  • Cephalosporin Administration to Patients with a History of Penicillin Allergy Adverse Reactions to Drugs, Biologicals and Latex Committee
    Work group report May, 2009 Cephalosporin Administration to Patients with a History of Penicillin Allergy Adverse Reactions to Drugs, Biologicals and Latex Committee Work Group Members : Roland Solensky, MD FAAAAI, Chair Aleena Banerji, MD Gordon R. Bloomberg, MD FAAAAI Marianna C. Castells, MD PhD FAAAAI Paul J. Dowling, MD George R. Green, MD FAAAAI Eric M. Macy, MD FAAAAI Myngoc T. Nguyen, MD FAAAAI Antonino G. Romano, MD PhD Fanny Silviu-Dan, MD FAAAAI Clifford M. Tepper, MD FAAAAI INTRODUCTION Penicillins and cephalosporins share a common beta-lactam ring structure, and hence the potential for IgE-mediated allergic cross-reactivity. Allergic cross-reactivity between penicillins and cephalosporins potentially may also occur due to presence of identical or similar R-group side chains, in which case IgE is directed against the side chain, rather the core beta-lactam structure. This work group report will address the administration of cephalosporins in patients with a history of penicillin allergy. First, published data will be reviewed regarding 1) cephalosporin challenges of patients with a history of penicillin allergy (without preceding skin testing or in vitro testing), and 2) cephalosporin challenges of patients proven to have a type I allergy to penicillins (via positive penicillin skin test, in vitro test or challenge). Secondly, 1 2/9/2011 recommendations on cephalosporin administration to patients with a history of penicillin allergy will be presented. Unless specifically noted, the term ‘penicillin allergy’ will be used to indicate an allergy to one or more of the penicillin-class antibiotics, not just to penicillin itself. The following discussion includes references, in certain clinical situations, to performing cephalosporin graded challenges in patients with a history of penicillin allergy.
    [Show full text]
  • Impact of Intramammary Treatment on Gene Expression Profiles in Bovine Escherichia Coli Mastitis
    Impact of Intramammary Treatment on Gene Expression Profiles in Bovine Escherichia coli Mastitis Anja Sipka1*, Suzanne Klaessig1, Gerald E. Duhamel2, Jantijn Swinkels3, Pascal Rainard4,5, Ynte Schukken1 1 Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States of America, 2 Department of Biomedical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, United States of America, 3 GD Animal Health Center, Deventer, The Netherlands, 4 INRA, UMR1282, Infectiologie Animale et Sante´ Publique, Nouzilly, France, 5 Universite´ Franc¸ois Rabelais de Tours, UMR1282 ISP, Tours, France Abstract Clinical mastitis caused by E. coli accounts for significant production losses and animal welfare concerns on dairy farms worldwide. The benefits of therapeutic intervention in mild to moderate cases are incompletely understood. We investigated the effect of intramammary treatment with cefapirin alone or in combination with prednisolone on gene expression profiles in experimentally-induced E. coli mastitis in six mid-lactating Holstein Friesian cows. Cows were challenged with E. coli in 3 quarters and received 4 doses of 300 mg cefapirin in one quarter and 4 doses of 300 mg cefapirin together with 20 mg prednisolone in another quarter. At 24 h (n = 3) or 48 h (n = 3) post-challenge, tissue samples from control and treated quarters were collected for microarray analysis. Gene expression analysis of challenged, un-treated quarters revealed an up-regulation of transcripts associated with immune response functions compared to un-challenged quarters. Both treatments resulted in down-regulation of these transcripts compared to challenged, un-treated quarters most prominently for genes representing Chemokine and TLR-signaling pathways.
    [Show full text]
  • Impact of Experimental Trauma and Niflumic Acid Administration on Antimicrobials’ Concentration in Serum and Mandible of Rats
    J Musculoskelet Neuronal Interact 2006; 6(3):242-246 Original Article Hylonome Impact of experimental trauma and niflumic acid administration on antimicrobials’ concentration in serum and mandible of rats A. Kotsiou1, M. Anagnostou2, C. Mourouzis2, G. Rallis3, Ch. Chantzi1, C. Tesseromatis2 1Aretaieion University Hospital Athens, 2Department of Pharmacology, Medical School, University of Athens, 3Department of Oral and Maxillofacial Surgery, General Hospital of Athens, Greece Abstract Administration of antibiotics and analgesics in surgery or trauma is of great importance for an effective treatment. Trauma, as stress stimulus, causes alterations in various functions of the organism as well as in drug pharmacokinetics. The aim of this study was to determine the effect of trauma upon the serum and bone levels of the antimicrobial ampicillin and cefapirin, with and without co-administration of a non-steroidal anti-inflammatory analgesic (NSAIDs). Fifty-six male Wistar rats were divid- ed into two groups A (control) and B (experimental). Each group consisted of 4 subgroups (n=7) receiving ampicillin, ampi- cillin with niflunic acid, cefapirin, and cefapirin with niflunic acid. In group B traumatic injury was performed by incision (7mm length) in the right cheek. The levels of the antibiotics were estimated by the inhibition zone of B. subtilis. An increase in antibiotic levels was observed in group B, being statistically significant only for cefapirin level in the mandible. Upon niflumic acid co-administration a statistically significant rise in serum ampicillin and mandible cefapirin levels was observed in both control and experimental groups (student t-test). It can be concluded that the combination of antibiotics and non-steroid anti- inflammatory drugs (NSAIDs) may enhance the antibacterial drug concentration.
    [Show full text]
  • Comparative Pharmacokinetics of Cephalosporin Antimicrobials and Accuracy of Allometric Scaling in Food-Producing and Companion Animals Femke J
    Taverne et al. BMC Veterinary Research (2016) 12:185 DOI 10.1186/s12917-016-0817-2 RESEARCH ARTICLE Open Access Modelling concentrations of antimicrobial drugs: comparative pharmacokinetics of cephalosporin antimicrobials and accuracy of allometric scaling in food-producing and companion animals Femke J. Taverne1,2,3*, Ingeborg M. van Geijlswijk1,3, Dick J. J. Heederik1,2, Jaap A. Wagenaar1,4,5 and Johan W. Mouton1,6 Abstract Background: To optimize antimicrobial dosing in different animal species, pharmacokinetic information is necessary. Due to the plethora of cephalosporin antimicrobials and animal species in which they are used, assessment of pharmacokinetics in all species is unfeasible. In this study we aimed to describe pharmacokinetic data of cephalosporins by reviewing the available literature for food producing and companion animal species. We assessed the accuracy of interspecies extrapolation using allometric scaling techniques to determine pharmacokinetic characteristics of cephalosporins in animal species for which literature data is unavailable. We assessed the accuracy of allometric scaling by comparing the predicted and the published pharmacokinetic value in an animal species/humans not included in the allometric modelling. Results: In general, excretion of cephalosporins takes place mainly through renal mechanisms in the unchanged form and volume of distribution is limited in all animal species. Differences in plasma protein binding capacity and elimination half-life are observed but available information was limited. Using allometric scaling, correlations between body weight (BW) and volume of distribution (Vd) and clearance (Cl) were R2 > 0.97 and R2 > 0.95 respectively for ceftazidime, ceftiofur, cefquinome and cefepime but not ceftriaxone. The allometric exponent ranged from 0.80 to 1.31 for Vd and 0.83 to 1.24 for Cl.
    [Show full text]
  • European Surveillance of Healthcare-Associated Infections in Intensive Care Units
    TECHNICAL DOCUMENT European surveillance of healthcare-associated infections in intensive care units HAI-Net ICU protocol Protocol version 1.02 www.ecdc.europa.eu ECDC TECHNICAL DOCUMENT European surveillance of healthcare- associated infections in intensive care units HAI-Net ICU protocol, version 1.02 This technical document of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Carl Suetens. In accordance with the Staff Regulations for Officials and Conditions of Employment of Other Servants of the European Union and the ECDC Independence Policy, ECDC staff members shall not, in the performance of their duties, deal with a matter in which, directly or indirectly, they have any personal interest such as to impair their independence. This is version 1.02 of the HAI-Net ICU protocol. Differences between versions 1.01 (December 2010) and 1.02 are purely editorial. Suggested citation: European Centre for Disease Prevention and Control. European surveillance of healthcare- associated infections in intensive care units – HAI-Net ICU protocol, version 1.02. Stockholm: ECDC; 2015. Stockholm, March 2015 ISBN 978-92-9193-627-4 doi 10.2900/371526 Catalogue number TQ-04-15-186-EN-N © European Centre for Disease Prevention and Control, 2015 Reproduction is authorised, provided the source is acknowledged. TECHNICAL DOCUMENT HAI-Net ICU protocol, version 1.02 Table of contents Abbreviations ...............................................................................................................................................
    [Show full text]
  • Directed Molecular Evolution of Fourth-Generation Cephalosporin Resistance in Wellington Moore Iowa State University
    Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2011 Directed molecular evolution of fourth-generation cephalosporin resistance in Wellington Moore Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Medical Sciences Commons Recommended Citation Moore, Wellington, "Directed molecular evolution of fourth-generation cephalosporin resistance in" (2011). Graduate Theses and Dissertations. 10107. https://lib.dr.iastate.edu/etd/10107 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Directed molecular evolution of fourth-generation cephalosporin resistance in Salmonella and Yersinia by Wellington Moore A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Biomedical Science (Pharmacology) Program of Study Committee: Steve Carlson, Major Professor Timothy Day Ronald Griffith Iowa State University Ames, Iowa 2011 ii TABLE OF CONTENTS LIST OF FIGURES………………………………………………………………………iii LIST OF TABLES………………………………………………………………………..iv ABSTRACT……………………………………………………………………………….v CHAPTER 1. INTRODUCTION…………………………………………………………1 Review of B-Lactam antimicrobials………………………………...………1
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]